Clinical Study on Gynoveda Ayurvedic Formulations in Women with Low Anti-M llerian Hormone (AMH) Level.

Clinical Study to Evaluate Efficacy and Safety of Gynoveda Ayurvedic Formulations (Vardhani, along with Poshini and Rutuja) on Ovarian Reserve in Women with Low Anti-M llerian Hormone (AMH) Level An Open-Label, Multi-center, Non-comparative, Prospective, Interventional Study. - NIL

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101510

Enrollment

200

Registered

2026-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N978- Female infertility of other origin

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Married Female patients diagnosed with primary or secondary infertility 2. Female subjects with AMH levels below 0.1 to 1 ng per ml 3. Regular menstrual cycle of 21 to 35 days 4. Subjects with normal Serum FSH level 5. Subjects with no IVF done within the last 1 year 6. Subjects willing to provide written informed consent and ready to comply with the study protocol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in serum AMH levelTimepoint: Screening Visit (up to 5 days), baseline visit, Day 30, Day 60, Day 90, and Day 120	—

Secondary

Measure	Time frame
Number of conceptions confirmed (UPT) 2. Ovulation as assessed through serial follicular monitoring 3. Size of matured dominant follicle through serial follicular monitoring 4. Change in endometrial thickness. 5. Global assessment for Overall change by subject and investigator 6. Tolerability of study medications as assessed by participants and investigator 7. Safety evaluation by assessing adverse events, clinical symptoms, signs, vitals and laboratory tests Timepoint: Screening Visit (up to 5 days), baseline visit, Day 30, Day 60, Day 90, and Day 120	—

Measure

Time frame

Number of conceptions confirmed (UPT) 2. Ovulation as assessed through serial follicular monitoring 3. Size of matured dominant follicle through serial follicular monitoring 4. Change in endometrial thickness. 5. Global assessment for Overall change by subject and investigator 6. Tolerability of study medications as assessed by participants and investigator 7. Safety evaluation by assessing adverse events, clinical symptoms, signs, vitals and laboratory tests Timepoint: Screening Visit (up to 5 days), baseline visit, Day 30, Day 60, Day 90, and Day 120

—

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Target Institute of Medical Education and Research Pvt. Ltd

targetinstitute@yahoo.com9322522252

Outcome results